BRIEF-Theravance Biopharma To Reduce Headcount By About 75%

Sept 15 (Reuters) - Theravance Biopharma Inc (TBPH):

* THERAVANCE BIOPHARMA, INC. (TBPH) ANNOUNCES STRATEGIC ACTIONS TO FOCUS ON RESPIRATORY DISEASE PORTFOLIO

* THERAVANCE BIOPHARMA INC (TBPH) - IMPLEMENTS SIGNIFICANT COST REDUCTION PROGRAM

* THERAVANCE BIOPHARMA INC (TBPH) - EXPECTS TO BE SUSTAINABLY CASH FLOW POSITIVE BEGINNING 2H 2022

* THERAVANCE BIOPHARMA INC (TBPH) - HEADCOUNT WILL BE REDUCED BY APPROXIMATELY 75%

* THERAVANCE BIOPHARMA INC (TBPH) - TOTAL ANNUALIZED OPERATING EXPENSE SAVINGS OF APPROXIMATELY $165 MILLION IN 2022

* THERAVANCE BIOPHARMA INC (TBPH) - 75% OF WORKFORCE REDUCTION EXPECTED TO BE COMPLETED IN NOVEMBER 2021 AND REMAINDER TO BE COMPLETED IN FEBRUARY 2022

* THERAVANCE BIOPHARMA INC (TBPH) - WILL HALT DEVELOPMENT OF ALL NON-RESPIRATORY DISEASE RELATED PROGRAMS

* THERAVANCE BIOPHARMA INC (TBPH) - DECIDED TO REDUCE SIZE OF ITS BOARD, AND ANNOUNCING RESIGNATIONS FROM BOARD OF GEORGE M. WHITESIDES AND ROBERT V. GUNDERSON Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.